Synapse - Michael Morris

Results (112)

Therapeutic implications of germline testing in patients with advanced cancers

Journal Article

Stadler, Z. K.; Maio, A.; Chakravarty, D.; Kemel, Y.; Sheehan, M.; Salo-Mullen, E.; Tkachuk, K.; Fong, C. J.; Nguyen, B.; Erakky, A.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

A phase II, nonrandomized open trial assessing pain efficacy with radium-223 in symptomatic metastatic castration-resistant prostate cancer

Journal Article

McHugh, D.; Tagawa, S.; Moryl, N.; Milowsky, M.; Heller, G.; Osborne, J.; Rathkopf, D.; Basch, E.; Pandit-Taskar, N.; Morris, M. J.
Clinical Genitourinary Cancer (2021)

Fulltext@MSK | Save

Phase 3 randomized controlled trial of androgen deprivation therapy with or without docetaxel in high-risk biochemically recurrent prostate cancer after surgery (TAX3503)

Journal Article

Morris, M. J.; Mota, J. M.; Lacuna, K.; Hilden, P.; Gleave, M.; Carducci, M. A.; Saad, F.; Cohn, E. D.; Filipenko, J.; Heller, G.; more...
European Urology Oncology (2021)

Fulltext@MSK | Save

Baseline testosterone levels in men with clinically localized high-risk prostate cancer treated with radical prostatectomy with or without neoadjuvant chemohormonal therapy (Alliance)

Journal Article

Eastham, J. A.; Heller, G.; Hillman, D. W.; Hahn, O. M.; Parsons, J. K.; Mohler, J. L.; Small, E. J.; Morris, M.
Journal of Urology (2021)

Fulltext@MSK | Save

Inferences about drug safety in phase III trials in oncology: Examples from advanced prostate cancer

Journal Article

Drago, J. Z.; Gönen, M.; Thanarajasingam, G.; Sacks, C. A.; Morris, M. J.; Kantoff, P. W.; Stopsack, K. H.
JNCI: Journal of the National Cancer Institute (2021)

Fulltext@MSK | Save

CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Rao, A.; Ryan, C. J.; VanderWeele, D. J.; Heller, G.; Lewis, L. D.; Watt, C.; Chen, R. C.; Grubb, R.; Hahn, O. M.; Beltran, H.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Use of bone modifying agents in patients with metastatic castrate-sensitive prostate cancer

Meeting Abstract

Mitchell, A. P.; Mishra, A. A.; Bach, P. B.; Morris, M. J.
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

CDK12 alterations define a distinct molecular subtype of prostate cancers with unique genomic and clinical characteristics

Meeting Abstract

Nguyen, B.; Mota, J. M.; Nandakumar, S.; Stopsack, K. H.; Weg, E.; Rathkopf, D.; Morris, M. J.; Scher, H.; Kantoff, P. W.; Gopalan, A.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Dickkopf-1 can lead to immune evasion in metastatic castration-resistant prostate cancer

Journal Article

Wise, D. R.; Schneider, J. A.; Armenia, J.; Febles, V. A.; McLaughlin, B.; Brennan, R.; Thoren, K. L.; Abida, W.; Sfanos, K. S.; De Marzo, A. M.; more...
JCO Precision Oncology (2020)

Fulltext@MSK | Save

Pan-cancer analysis of CDK12 alterations identifies a subset of prostate cancers with distinct genomic and clinical characteristics

Journal Article

Nguyen, B.; Mota, J. M.; Nandakumar, S.; Stopsack, K. H.; Weg, E.; Rathkopf, D.; Morris, M. J.; Scher, H. I.; Kantoff, P. W.; Gopalan, A.; more...
European Urology (2020)

Fulltext@MSK | Save